The other was an ipsilateral Grade 2 ER/PR- HER2 + recurrence with associated DCIS 8 months following first surveillance CEM and 15 months following BCS where the patient did not complete recommended adjuvant therapy. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.